What Amifos Treats: Main Uses and Benefits

Amifos is generally used across domains where additional symptomatic support is needed, primarily applied to help mitigate organ-specific functional stress caused by cancer treatments. The medication is relevant in clinical settings for conditions that include the potential for cumulative renal toxicity associated with repeated administration of cisplatin chemotherapy, and moderate-to-severe xerostomia (chronic dry mouth) resulting from radiation therapy for head and neck cancers.

This supportive agent helps address symptoms linked to organ-specific functional stress caused by the toxic treatments.

“This application provides support that helps ease the overall symptom burden, particularly by addressing the risk of high-severity organ damage.”

The key therapeutic benefit contributes to supporting functional stability, which helps patients cope more steadily during difficult episodes and may assist with the potential to maintain the prescribed anti-cancer regimen. The use for xerostomia contributes to improved comfort during symptomatic periods, and is commonly used to help with the severity of this disruptive manifestation.

---

Quick Fact: Relief for Treatment-Induced Toxicity

Area of Support	Target Condition or Symptom	Primary Benefit
Chemotherapy	Cumulative renal toxicity	Supports kidney function and stability
Radiotherapy	Chronic dry mouth (xerostomia)	Eases severity and improves comfort

Eligibility Map: Who Can and Cannot Use Amifos — Official Regulatory Information

The eligibility profile for Amifostine is strictly defined by regulatory authorities and centers on underlying conditions, the type of cancer therapy received, and patient status.

Populations for Whom Use is Contraindicated

Classification	Restricted Group or Condition
Absolute Prohibition	Known hypersensitivity to aminothiol compounds (the drug’s chemical class).
Treatment Restriction	Patients receiving curative-intent chemotherapy or definitive radiotherapy for other malignancies, except in a clinical study setting.
Status Restriction	Patients who are hypotensive (low blood pressure) or significantly dehydrated.

Age and Conditional Use Rules

• Pediatric Use: Safety and effectiveness have not been established; Amifostine is not recommended for use in children.
• Geriatric Use: Dose selection requires caution in older adults, reflecting the greater frequency of age-related declines in renal or hepatic function.
• Pre-existing Conditions: Patients with a history of cardiovascular conditions (e.g., heart disease, arrhythmias) or cerebrovascular conditions (e.g., stroke) must use the medicine with particular care and close monitoring.

Pregnancy and Lactation Eligibility

Use during pregnancy is restricted to circumstances where the potential benefit justifies the potential risk, as the drug has been shown to be embryotoxic in animal studies. It is recommended that breastfeeding be discontinued while the mother is undergoing treatment.

Interactions with other medicines and products

The official regulatory profile for Amifostine is defined by a primary pharmacodynamic interaction with specific classes of medicinal products. This interaction relates to the drug's potential to cause or potentiate hypotension (low blood pressure) when administered alongside other blood pressure-lowering agents.

Documented Interaction Patterns

Category	Officially Documented Pattern
Interacting Drug Class	Anti-hypertensive medications and other drugs that could cause or potentiate hypotension.
Mechanism	Pharmacodynamic interaction resulting in additive hypotensive effects.
Timing Restriction	Anti-hypertensive therapy must be temporarily discontinued for at least 24 hours prior to Amifostine administration.
Regulatory Restriction	Co-administration is restricted (not recommended) if the required 24-hour interruption of anti-hypertensive therapy is not possible.
Population Note	Special care is required for patients with preexisting cardiovascular or cerebrovascular conditions, as the hypotensive interaction may have more serious consequences in these groups.

Pharmacokinetic Interaction Status

Official prescribing information notes the absence of documented exposure-altering interactions for certain co-administered drugs. For instance, the pharmacokinetics of Amifostine are stated to be unaffected by pretreatment with dexamethasone or metoclopramide.

There are no documented interactions with food, alcohol, herbal products, or supplements specified in the official regulatory labeling. The interaction profile is strictly focused on the potentiation of hypotension.

How Amifos Works

Amifostine's mechanism relies on selective cellular shielding, which is initiated by the bioconversion of the inactive prodrug into its active metabolite, WR-1065. The enzyme alkaline phosphatase catalyzes this essential dephosphorylation. The metabolite, WR-1065, then exhibits selective cellular uptake, accumulating preferentially in non-malignant tissues, a process influenced by higher pH and increased vascularity in these areas.

Chemical Scavenging and Cellular Protection

Once concentrated intracellularly, WR-1065 acts as a chemical scavenger. Its thiol group directly neutralizes highly destructive molecules, including free radicals and electrophilic metabolites generated by co-administered treatments. By quenching these reactive species, the mechanism prevents molecular injury to critical cellular components, such as DNA and lipids. This action contributes directly to the stability of renal and neural cellular structures by reducing oxidative stress damage. The mechanism also involves the modulation of DNA repair pathways and temporary G2/M cell cycle arrest in non-malignant cells, augmenting their intrinsic ability to recover from insult.

How to Use Amifos

Amifos (Amifostine) is administered exclusively as a time-critical Intravenous (IV) infusion in a clinical setting. The usage pattern is tied directly to the accompanying anti-cancer treatment, requiring administration immediately beforehand.

---

Official Administration Procedures

Amifos is supplied as a lyophilized powder (500 mg per vial) and requires precise preparation before use. The powder must be reconstituted and subsequently diluted using only 0.9% Sodium Chloride Injection, USP, before the IV infusion. The final administration is subject to context-specific timing and duration rules.

Clinical Context	Dose (mg/m^2)	Timing Relative to Treatment	Infusion Duration	Dosing Frequency
Cisplatin Therapy	910 mg/m^2 (initial)	Starts 30 minutes prior to chemotherapy	15 minutes (must not be exceeded)	Once daily, prior to each course
Radiation Therapy	200 mg/m^2	Starts 15 to 30 minutes prior to radiation fraction	3 minutes	Once daily, prior to each fraction

---

Procedural Conditions and Special Use Rules

Standard procedures require the patient to be adequately hydrated and remain in a supine position during the infusion. For the higher dose (910 mg/m^2), if the full amount cannot be successfully administered, the dose for subsequent courses is reduced to 740 mg/m^2. No specific dose adjustments are provided for older adults or those with renal or hepatic impairment, and the medicine is generally not recommended for use in pediatric patients due to lack of established data.

Research Evidence / Overview of Studies for Amifos

This overview provides a patient-friendly summary of the official clinical research and study landscape for Amifostine (Amifos), drawing from regulatory reviews and peer-reviewed clinical trials. The discussion focuses only on the types of studies that have been conducted, the research questions that were explored, and the patterns that were observed in the study populations, without offering any clinical guidance, treatment recommendations, or interpretation of results.

---

Evidence for Use in Kidney Protection During Cisplatin Treatment

The research for this application was mainly conducted through Randomized Controlled Trials (RCTs), which are the primary source of clinical evidence. These studies were designed to explore the use of Amifostine alongside specific, often high-dose, cisplatin-based chemotherapy regimens in adult patients.

What the studies suggest: Findings describe patterns observed in the studies where the use of Amifostine was explored in relation to measures of kidney function decline compared to control groups. The data show patterns related to maintaining the scheduled treatment; research describes patterns associated with the continuation of scheduled treatment cycles for patients receiving Amifostine. The research also describes patterns where the use of Amifostine did not appear to interfere with the measures of anti-tumor efficacy, such as overall survival, within the trial context.

---

Evidence for Use in Reducing Chronic Dry Mouth from Radiation Therapy

The evidence for Amifostine in this context was derived from large Randomized Controlled Trials (RCTs) and systematic literature reviews. These studies were conducted in research contexts exploring the outcomes of radiation therapy.

What the studies suggest: The findings describe patterns observed in the studies where research described patterns associated with measured changes in the severity of dry mouth (xerostomia). Studies report how symptoms evolved in the observed populations, and described patterns of measured saliva flow rates in the Amifostine group during follow-up.

---

Research Gaps and What Remains Uncertain About Amifos

Certainty remains low regarding the full long-term effects on organ function stability, as follow-up durations were limited in many of the functional outcome assessments. The evidence quality varies across studies, and some initial findings were mixed, which contributes to the known research limitations. Comparative evidence is lacking regarding the use of Amifostine alongside some of the newest treatment delivery methods, making the utility in those emerging scenarios a question where data are still emerging and research is ongoing.

Common questions about Amifos (FAQ)

---

Q: Can Amifos be used for all types of cancer chemotherapy to prevent side effects?

Official regulatory indications for Amifos describe its use in reducing the incidence of cumulative kidney toxicity with repeated cisplatin administration in advanced ovarian cancer. It is also indicated for reducing the severity of dry mouth (xerostomia) from radiation treatment for head and neck cancer. Other uses are generally not recommended outside of a clinical study setting.

---

Q: How long after mixing can the Amifos solution be used?

Once the lyophilized powder is reconstituted and diluted with Sodium Chloride Injection by the healthcare provider, the solution is stable for a limited time. Official product information states it can be handled for up to 5 hours at room temperature (approximately 25 C) or up to 24 hours if kept refrigerated (2 C to 8 C). For administration, the solution is handled according to these time frames to maintain stability.

---

Q: Is there a dose adjustment for patients with kidney or liver problems?

Official product labeling states that no specific dose adjustments have been established for use in patients with pre-existing kidney (renal) or liver (hepatic) impairment. However, caution is advised when prescribing the medication to older adults, as they may have age-related decreases in these functions.

---

Q: What should I do if my blood pressure drops too low during the infusion?

If a significant drop in blood pressure (hypotension) occurs during the infusion, regulatory guidance states that the infusion should be immediately interrupted. The healthcare team will place the patient in a supine position (lying flat) and manage the blood pressure to ensure it returns to an acceptable level before potentially resuming the infusion.

---

Q: Why must anti-hypertensive medicine be stopped 24 hours before Amifos?

The requirement to stop anti-hypertensive (blood pressure-lowering) medicines for at least 24 hours prior is mandated to mitigate the risk of severe hypotension during the Amifos infusion. This restriction is necessary because Amifos can cause an additive effect, intensifying the blood pressure-lowering action of these other medicines.

---

Q: Will Amifos affect the results of my blood tests?

The official safety profile notes that Amifos can cause Hypocalcemia, which means a decrease in blood calcium levels. Because this is a documented risk, monitoring of serum calcium levels is part of the clinical management for some patients while undergoing treatment.

---

Q: Does Amifos require any special monitoring while I'm getting the infusion?

Yes, official product information outlines specific monitoring parameters and conditions during administration. Patients are required to be kept in a supine position (lying flat). Blood pressure monitoring is required before, throughout (periodically), and after the infusion, particularly with the higher dose, to manage the risk of hypotension.

How to Store and Dispose of Amifos

Amifos (amifostine) for injection is supplied as a lyophilized powder and requires specific storage and handling to maintain its stability and ensure safe disposal.

---

Storage Conditions

The unopened vials must be stored at Controlled Room Temperature, which is 20 C to 25 C. The powder should be preserved in its original carton for protection from light and must not be frozen. The drug must also be stored out of the sight and reach of children.

Stability and Disposal

Once reconstituted with 0.9% Sodium Chloride Injection, the solution is stable for up to 5 hours at room temperature or up to 24 hours under refrigeration (2 C to 8 C). Healthcare professionals must follow special handling and disposal procedures for unused product, as amifostine is classified as a hazardous medicinal product requiring disposal according to local regulations.